Article Text

Download PDFPDF
Gamma hydroxybutirate use for sexual assault
  1. M Varela1,
  2. S Nogué2,
  3. M Orós3,
  4. Ò Miró1
  1. 1Emergency Department, Hospital Clínic, Barcelona, Spain
  2. 2Toxicology Unit, Hospital Clínic, Barcelona
  3. 3Forensic Department, Barcelona
  1. Correspondence to:
 Dr Ò Miró
 Emergency Department, Hospital Clínic, Villarroel 170, 08036 Barcelona, Catalonia, Spain;


The use of gamma hydroxybutyrate (GHB) as a recreational drug has quickly spread among European young people during the past decade. Although it has been claimed that GHB can be potentially used to facilitate sexual assault, no case reports have been previously described. A case is described in which GHB was used with that criminal purpose and a review of previous literature is undertaken.

  • gamma hydroxybutirate
  • liquid ecstasy
  • rape
  • sexual assault

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

An estimated 20% of adult women, 15% of college aged women, and 12% of adolescent girls have experienced sexual assault or sexual abuse.1 Drug facilitated sexual assault has increasingly occurred in the past few years, and gamma hydroxybutyrate (GHB), best known by the street name of “liquid ecstasy”, has repeatedly been claimed as one of the most commonly used for this purpose. However, objective analytical data demonstrate that GHB is much more unusual than expected and that ethanol is by far the substance more frequently found (table 1).2,3 None the less, as nothing is reported in these studies about whether drugs were voluntarily consumed by the victim or intentionally used by the perpetrator to gain his/her control, the true role for each drug in sex crimes remains to be defined.

Table 1

Substances identified in 3212 suspected cases of drug facilitated sexual assault2,3

We report a case in which GHB use as sexual assault facilitator seems to be present and we also review previous literature.


A 20 year old woman presented herself to the emergency department suspecting that she had probably been sexually assaulted. The previous night she had been dancing in a discotheque, she had had two drinks and smoked cigarettes, but denied any illegal drug use. At this point, she had a gap in her memory. Her next memory was that she woke up in bed in a strange flat with two unknown men who took her to the street, left her, and disappeared.

She complained of mild proctalgia and vulvodynia. Her medical history was irrelevant. The patient had been sexually active from the age of 17. Physical examination was only remarkable for the presence of a recent haematoma on the inside of the right thigh. The external and internal genitalia, perineum, and anus were normal, and the hymen was broken and healed, and presence of spermatozoa in vaginal samples was confirmed by optic microscopy. Psychiatric evaluation uncovered no psychopathological data apart from a reactive depression.

The routine screening of the urine sample (enzyme immunoassay, ACA Star) for opioids, cocaine, cannabis, amphetamines, benzodiazepines, and ethanol was negative. A further determination of GHB by gas chromatography selected ion monitoring mass spectrometry (HP5971) was requested and confirmed as positive.


GHB was initially developed and used as an anaesthetic inductor, but its use in medicine progressively decreased because of its low analgesic properties and high incidence of secondary effects. Conversely, GHB recreational use rapidly spread to most developed countries during the past decade.4 In Catalonia, despite the fact that the first cases were described during 1999,5 more than 100 cases have been reported by a single institution only two years later.6 Users especially appreciate its euphoric, disinhibitory, sedative and anabolic effects and some people have also mentioned aphrodisiac properties. GHB is quickly and effectively absorbed in the stomach, achieves a blood peak in few minutes, easily reaches the central nervous system, and has a short half life (27 minutes), being expelled unchanged by the kidneys. GHB is not detectable in urine after 12 hours.2 The main clinical effect of GHB overdose is a decrease of consciousness, which is usually manifested about 15 minutes after oral administration and persists for about three hours on average. In up to 17% of patients arriving at the emergency department because of GHB overdose, a deep coma (Glasgow Consciousness Scale of 3 points) is present.6

Since GHB has been banned in most countries, consumers have increasingly changed the use of GHB by gamma butyrolactone and/or 1,4 butanediol. These industrial solvents are precursors of GHB and are comparatively easy to obtain. In fact, they can be brought via the internet. Although the relevance of this shift has not been studied in Catalonia, gamma butyrolactone and 1,4 butanediol is though to be the cause of a significant number of GHB overdoses in many parts of the world, specially in Australia and United States.7–11

The most typical street presentation of GHB is as a colourless and odourless liquid with a very slightly salty taste; GHB can therefore be mixed with drinks with no appreciable change in their organoleptic characteristics. This, together with the pharmacokinetic and pharmacodynamic properties referred to above, makes GHB ideal for drug facilitated sexual assaults, especially when it is considered that GHB also causes passivity, loss of will to resist, relaxation of voluntary muscles, and lasting anterograde amnesia concerning events occurring under the influence of the drug. However, no individual case reports have been reported confirming this hypothesis to date. It is possible that analytical difficulties surrounding GHB determination (especially the necessity of a targeted analysis for detection because of GHB is not routinely included in current toxicological drug abuse screenings) is contributing to the lack of data regarding this issue.

The symptoms manifested by the patient in this case report are consistent with the known pharmacological effects of GHB. GHB has been shown to act synergistically with other central nervous system depressants such as ethanol. Symptoms may also mimic those of alcohol and not all patients are screened for GHB. For all these reasons we want to emphasise the importance of GHB (and precursors) being considered with any causes of sexual assault, and should be included with any drugs of abuse screen that is done in these cases.